Psychiatry Research
Volume 136, Issue 1 , Pages 1-6, 15 July 2005

Substance P in serum and cerebrospinal fluid of depressed patients: No effect of antidepressant treatment

  • Michael Deuschle

      Affiliations

    • Central Institute of Mental Health Mannheim, University of Heidelberg, J 5, 68159 Mannheim, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 621 1703 2321; fax: +49 621 1703 2325.
    • ,
  • Peter Sander

      Affiliations

    • Central Institute of Mental Health Mannheim, University of Heidelberg, J 5, 68159 Mannheim, Germany
    • ,
  • Inga Herpfer

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Freiburg Medical School, Hauptstr. 5, 79104 Freiburg, Germany
    • ,
  • Bernd L. Fiebich

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Freiburg Medical School, Hauptstr. 5, 79104 Freiburg, Germany
    • ,
  • Isabella Heuser

      Affiliations

    • Central Institute of Mental Health Mannheim, University of Heidelberg, J 5, 68159 Mannheim, Germany
    • Department of Psychiatry and Psychotherapy, Charité University Hospital, Campus Benjamin Franklin, Eschenallee 3, 14050 Berlin, Germany
    • ,
  • Klaus Lieb

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Freiburg Medical School, Hauptstr. 5, 79104 Freiburg, Germany

Received 7 January 2004; received in revised form 8 November 2004; accepted 18 December 2004.

Abstract 

The neuropeptide substance P (SP) and its receptor, the neurokinin receptor-1 (NK-1), have been associated with some aspects of the pathophysiology of depression. There is limited information available about the effects of antidepressant treatment on serum and cerebrospinal fluid (CSF) concentrations of SP. We measured serum levels of SP in 78 depressed patients after a 6-day medication washout period, as well as after 14 and 35 days of antidepressant treatment with either paroxetine or amitriptyline. In 11 patients, SP was determined in CSF both before and after treatment. Eleven healthy male subjects served as controls. Baseline SP concentrations were independent of age, gender and severity of depression. Neither the total group nor subgroups showed significant differences in SP serum concentrations. SP concentrations in CSF did not change significantly in the patients during treatment, but there was a trend for an increase in paroxetine-treated patients. Serum SP concentrations were not related to treatment response or the class of antidepressant administered. Our data do not support the hypothesis that changes in SP levels in serum or CSF are related to antidepressant response.

Keywords: Depressive disorder, Course, Treatment, Antidepressant, Paroxetine, Amitriptyline

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0165-1781(05)00138-1

doi:10.1016/j.psychres.2004.12.007

Psychiatry Research
Volume 136, Issue 1 , Pages 1-6, 15 July 2005

Article Tools

* Image Usage & Resolution